Table 1—

Baseline demographics

Placebo TIDPramlintide 90 μg BIDPramlintide 120 μg BID
n (ITT)161171166
Sex (% M/F)52/4849/5148/52
Age (years)56.4 ± 10.257.0 ± 10.256.9 ± 10.5
Race (%)
 White757773
 Black121413
 Hispanic12813
 Other111
Body weight (kg)*96.8 ± 20.597.1 ± 19.396.7 ± 23.2
BMI (kg/m2)33.7 ± 7.233.8 ± 6.334.1 ± 7.5
Diabetes duration (years)*12.4 ± 7.012.0 ± 6.612.1 ± 7.3
HbA1c (%)*9.3 ± 1.39.1 ± 1.19.0 ± 1.1
Concomittant therapiesWeek 0Week 52Week 0Week 52Week 0Week 52
Total daily insulin dose (units)*747670726970
Type of insulin used (%)
 Short-acting only001210
 Long-acting only141521191718
 Short- and long-acting868578798282
Injections/day (%)
 1 injection957698
 2 injections687373727270
 3+ injections232220221922
Oral anti-hyperglycemic agents, (%)272726232321
 Metformin only1414131399
 Sulfonylureas only101279910
 Metformin and sulfonylureas226555
  • *

    * Values are mean ± standard deviation;

  • proportion of subjects